Table 1.

Summary of most significant CAR‐T cell therapy advances. Adapted from the Annual Report of the American Society of Clinical Oncology (ASCO), 2018^[ 1 ^]

Disease	CAR‐T cell therapy	Response ratio (period)	Remission ratio	Ref.
ALL	Kymriah (CTL019)	90% (5 years after diagnosis)	82%	[ 7 ]
DLBCL	Kymriah (CD19)	80% (6 month after treatment)	43%	[ 8 ]
Refractory NHL	Yescarta (ZUMA‐1)	40% (9 month after treatment)	54%	[ 9 ]
Multiple myeloma	BCMA CAR‐T	31% (>6 months after treatment)	94%	[ 10 ]

ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B‐cell lymphoma; NHL, non‐Hodgkin lymphoma; BCMA, B‐cell maturation antigen.